Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
16 Maio 2024 - 9:00AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that management will present a corporate overview at the
Alliance Global Partner’s Healthcare Showcase taking place
virtually on Tuesday, May 21, 2024.
Presentation
Details: |
Date: |
Tuesday, May 21, 2024 |
Time: |
11:00 am EST |
Webcast: |
Click HERE to register for the
conference and view the presentation |
|
|
Management will be available for one-on-one
meetings with investors who are registered for the conference.
About Aspira Women’s Health
Inc.Aspira Women’s Health Inc. is dedicated to the
discovery, development, and commercialization of noninvasive,
AI-powered tests to aid in the diagnosis of gynecologic
diseases.
OvaWatch® and Ova1Plus® are offered to clinicians
as OvaSuiteSM. Together, they provide the only comprehensive
portfolio of blood tests to aid in the detection of ovarian cancer
for the 1.2+ million American women diagnosed with an adnexal mass
each year. OvaWatch provides a negative predictive value of 99% and
is used to assess ovarian cancer risk for women where initial
clinical assessment indicates the mass is indeterminate or benign,
and thus surgery may be premature or unnecessary. Ova1Plus is
comprised of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to
expand our ovarian cancer portfolio and addresses the tremendous
need for noninvasive diagnostics for endometriosis, a debilitating
disease that impacts millions of women worldwide. In ovarian
cancer, our OvaMDxSM risk assessment is designed to combine
microRNA and protein biomarkers with patient data to further
enhance the sensitivity and specificity of our current tests. In
endometriosis, EndoCheckSM is the first-ever noninvasive test
designed to identify endometriomas, one of the most commonly
occurring forms of endometriosis. The EndoMDxSM test is designed to
combine microRNA and protein biomarkers with patient data to
identify all endometriosis.
Investor Relations
Contact: Torsten Hombeck, Ph.D. Chief Financial
Officer Aspira Women’s HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024